Sheheryar Kabraji

New Capabilities

Senior author on a GLP-1 and triple-negative breast cancer study being presented at ASCO 2026 on June 1

A study of more than 12,000 patients found that those taking GLP-1 weight-loss drugs were 38% to 50% less likely to progress to stage IV cancer in four obesity-linked cancers. Cleveland Clinic led the study. Researchers compared GLP-1 users — on drugs like Ozempic, Wegovy, and Mounjaro — against patients taking older diabetes pills.

Updated May 24